Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cadrenal Therapeutics, Inc. ( (CVKD) ) just unveiled an announcement.
On July 15, 2025, Robert Lisicki resigned from the board of directors of Cadrenal Therapeutics, Inc., with no disagreements cited regarding company operations or policies. The company has announced its 2025 annual meeting of stockholders will be held on September 24, 2025, with a record date set for July 28, 2025, for voting eligibility. Revised deadlines for stockholder proposals have been provided, requiring submissions by July 28, 2025, to be included in the proxy materials.
The most recent analyst rating on (CVKD) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Underperform.
The overall score reflects significant financial challenges, including ongoing losses and no revenue generation, which weigh heavily on the company’s outlook. Technical indicators suggest limited momentum, while valuation metrics highlight difficulties in assessing the stock’s fair value. Despite a positive corporate development with the appointment of a new Chief Medical Officer, the fundamental financial weaknesses remain the dominant concern.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Average Trading Volume: 26,774
Technical Sentiment Signal: Sell
Current Market Cap: $21.97M
Learn more about CVKD stock on TipRanks’ Stock Analysis page.